| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2011: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Research Abstract |
Oral mucositis is a dose-limiting toxicity in cancer chemotherapy. However, at present, no effective causal prophylaxis or treatment for oral mucositis is established in Japan. In USA and Europe, incidents of chemotherapy-induced mucositis was treated by topical oral G-CSF (Granulocyte-colony stimulating factor). We report that we have produced a topical oral G-CSF mouthrinses and used it to treat oral mucositis in Japanese cancer patients. G-CSF (filgrastim) was administered as a mouthrinses (carboxymethylcellulose 2%) at a dose of 4x75ug/day for 5 days against severe mucositis (NCI-CTCAEv3.0 grade 3 or 4). Result: Severe mucositis was reduced significantly and both eating difficulties and oral pain were improved. In conclusion, topical oral G-CSF mouthrinses may be beneficial in reducing oral mucositis and improving the quality of life.
|
